October 2025 SCRI Release Copied
SCRI Trials and Trial Regimen Updates
The following updates were completed between Sept. 19 – Oct. 21, 2025. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.
For questions about these trials and regimens, please contact SCRIiKMEMRedits@McKesson.com.
New Builds Completed
| Study Number | Notes for New Build |
| 24196 | USOR 24196 CH 02 Phase 3 Mezagitamab (TAK-079) or Placebo Q56D |
| 25109 | USOR 25109 GYN 160 Phase 3 Doxorubicin Q21D – v2.0 24JUL2025
USOR 25109 GYN 160 Phase 3 Paclitaxel Q28D – v2.0 24JUL2025 USOR 25109 GYN 160 Phase 3 Rina-S Q21D – v2.0 24JUL2025 |
| 24103 | USOR 24103 MM 187 Phase 3 Anitocabtagene Autoleucel D1 – 27Feb2025
USOR 24103 MM 187 Phase 3 Carfilzomib D1,2,8,9,15,16 + Dexamethasone Q28D – 27Feb2025 USOR 24103 MM 187 Phase 3 Carfilzomib D1,8,15 + Dexamethasone Q28D – 27Feb2025 USOR 24103 MM 187 Phase 3 Daratumumab (IV) + Carfilzomib D1,2,8,9,15,16 + Dexamethasone Q28D – 27Feb2025 USOR 24103 MM 187 Phase 3 Daratumumab (IV) + Carfilzomib D1,8,15 + Dexamethasone Q28D – 27Feb2025 USOR 24103 MM 187 Phase 3 Daratumumab (IV) + Pomalidomide + Dexamethasone Q28D – 27Feb2025 USOR 24103 MM 187 Phase 3 Daratumumab (IV; C1 split dosing) + Carfilzomib D1,2,8,9,15,16 + Dexamethasone Q28D – 27Feb2025 USOR 24103 MM 187 Phase 3 Daratumumab (IV; C1 split dosing) + Carfilzomib D1,8,15 + Dexamethasone Q28D – 27Feb2025 USOR 24103 MM 187 Phase 3 Daratumumab (IV; C1 split dosing) + Pomalidomide + Dexamethasone Q28D – 27Feb2025 USOR 24103 MM 187 Phase 3 Daratumumab (SQ) + Carfilzomib D1,2,8,9,15,16 + Dexamethasone Q28D – 27Feb2025 USOR 24103 MM 187 Phase 3 Daratumumab (SQ) + Carfilzomib D1,8,15 + Dexamethasone Q28D – 27Feb2025 USOR 24103 MM 187 Phase 3 Daratumumab (SQ) + Pomalidomide + Dexamethasone Q28D – 27Feb2025 USOR 24103 MM 187 Phase 3 Fludarabine + Cyclophosphamide D-5,-4,-3 – 27Feb2025 USOR 24103 MM 187 Phase 3 Pomalidomide + Bortezomib + Dexamethasone Q21D – 27Feb2025 |
| 24160 | USOR 24160 MULTI 92 Phase 2 Part B IBI363 Intended Dose Q21D – v2.0 08MAY2024
USOR 24160 MULTI 92 Phase 2 Part B IBI363 Intended Dose Q28D – v2.0 08MAY2024 USOR 24160 MULTI 92 Phase 2 Part B IBI363 Priming Dose Q28D – v2.0 08MAY2024 USOR 24160 MULTI 92 Phase 2 Part B IBI363 Priming Dose Q35D – v2.0 08MAY2024 |
| 24211 | USOR 24211 MULTI 97 Phase 2a DB-1311 Q21D v8 13MAR2025 |
| MCCR RM 1263 |
RM 1263 Phase 1 Part A Cohort 1A1 AVZO-1418 Q28D – v4.0 22JUL2025
RM 1263 Phase 1 Part A Cohort 1A2 AVZO-1418 Q21D – v4.0 22JUL2025 RM 1263 Phase 1 Part B Cohort 1B1 AVZO-1418 + Pembrolizumab Q21D – v4.0 22JUL2025 RM 1263 Phase 1 Part B Cohort 1B1 AVZO-1418 + Pembrolizumab Q28D – v4.0 22JUL2025 RM 1263 Phase 1 Part B Cohort 1B2 AVZO-1418 + Osimertinib Q21D – v4.0 22JUL2025 RM 1263 Phase 1 Part B Cohort 1B2 AVZO-1418 + Osimertinib Q28D – v4.0 22JUL2025 |
| 24333 | USOR 24333 GU 270 Phase 2 Arm 1 JSB462 + Abiraterone Q28D – v01 15APR2025
USOR 24333 GU 270 Phase 2 Arm 2 JSB462 + Abiraterone Q28D – v01 15APR2025 USOR 24333 GU 270 Phase 2 Arm 3 ARPI (Abiraterone or Enzalutamide) Q28D – v01 15APR2025 |
| 24040 | USOR 24040 MM 191 Phase 2 Isatuximab + Carfilzomib + Dexamethasone Q28D |
Updated Reference Information
| Study Number | Updated Reference Information | Updated Regimen Instructions | Other Changes |
| 24168 | Amendment V06, 31MAR2025 | N/A | Updated drug; instructions |
| 22095 | PA v9.0: 01 May 2025 | Regimen Comments; Admin, Prophylaxis, Premedication | Updated Drug; Admin/Prep, Prep, Name, Premedication, and Frequency |
| 22260 | PA v4.0 | New Regimen.
Regimen comments; prophylaxis |
Updated Drug; Premedication, procurement |
| 22298 | PA v10.0; 09 July 2025 | Regimen comments; Prophylaxis, observation, and premedication | Updated Drug; Instructions. New Arm(s) |
| 22320 | PA v4: 13 Feb 2025 | Regimen Comments; Prophylaxis | Update Drug; Admin/Prep, Instructions, and Premedication |
| 22332 | PAv02: 08Jan2025 | Regiment comments; Admin and Prophylaxis | Update drug; Dose/Form and Premedication |
| 23080 | PA v3.1: 05 May 2025 | N/A | Update drug; instructions and premedication |
| 23084 | Sponsor Clarification: remove 12mg vial wording until official release | N/A | Update Drug; Instructions |
| 23120 | Site request | N/A | Updated Drug; Name |
| 23235 | PM; v4.0; 22 August 2025 | N/A | Update drug; instructions and premedication |
| 23292 | PA v19.0; 18 July 2025 | N/A | Update drug; procurement |
| 23297 | Memo 12 Jun 2025 Memo 14 Jul 2025 |
N/A | New Arms |
| 23325 | PA v2.1; 07 July 2025 | Regimen comments; Admin and Observation | Update drug; instructions and premedication |
| 24139 | PA4 v7.0: 10 Jun 2025 | Regimen comments; prophylaxis | Update drug; instructions, premedication, and procurement. |
| 24157 | PA v4.0; 09 May 2025 | Regimen comments; administration | Update Drug; premedication, procurement |
| 24170 | PM v4.0; 05 Sept 2025 | N/A | Update drug; instructions |
| 24240 | Amendment 9, 21APR2025 | Regimen comments; admin, prophylaxis, and premedication | Added Drug. Updated drug; admin/prep, dose/frequency |
| 24326 | PA V3.0: 23 Jun 2025; PCL 22Aug2025 |
Regimen comments; administration and prophylaxis | Update drug; instructions. New Arm(S) |
| 25017 | PM; v2.0; 11 Aug 2025 | N/A | Update drug; dose/frequency |
| 25023 | PA v4; 15 Aug 2025 | Regimen Comments; prophylaxis | Update drug; instructions and premedication |
| 22067 | PA v5.7; 17 July 2025 Memo; 21 July 2025 |
Regimen comments; administration, prophylaxis, and premedication | Update drug; instructions |
| 24189 | PA v1.0: 06 Jun 2025 | Regimen comments; premedication | Update drug; instructions and premedication |
| 23185 | Version 5.0. 29AUG2025 | N/A | Update drug; instructions and name |
| 24076 | PA v1.3: 31 Mar 2025 | Regimen comments; administration | Update drug; admin/prep |
| 24265 | PCL: 12 Sep 2025 | Regimen Comments; observation | Update drug; instructions |
| 24014 | Version 2.0; 25 July 2025 DIL; 24 July 2025 PACL; 31 July 2025 |
N/A | Update drug; instructions and premedication.
Closed Arm(s) |
| 23337 | Version 3.0, 01MAY2025 | Regimen Comments; prophylaxis | Update Drug; admin/prep, premedication.
Added Drug. |
| 24103 | PA 1: 27 Feb 2025 | Regimen comments; administration | N/A |